| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
Advances in Brief |
omiej Masoj
1
bniak1omiej Gliniewicz2
bieta Zowocka1 Posmyk3
ski1
1 International Hereditary Cancer Center, Department of Genetics and Pathology, Pomeranian Medical University, Szczecin, Poland; 2
Clinic of Urology, Pomeranian Academy of Medicine, Szczecin, Poland; 3
Regional Oncology Hospital, Biaystok, Poland; 4
Regional Oncology Hospital, Olsztyn, Poland; 5
Department of Obstetrics and Perinatology, Pomeranian Medical University, Szczecin, Poland; 6
Centre for Research on Women’s Health, Toronto, Ontario, Canada
Variants in the CHEK2 have been found to be associated with prostate cancer risk in the United States and Finland. We sequenced CHEK2 gene in 140 Polish patients with prostate cancer and then genotyped the three detected variants in a larger series of prostate cancer cases and controls. CHEK2 truncating mutations (IVS2 + 1G>A or 1100delC) were identified in 9 of 1921 controls (0.5%) and in 11 of 690 (1.6%) unselected patients with prostate cancer [odds ratio (OR) = 3.4; P = 0.004]. These mutations were found in 4 of 98 familial prostate cases (OR = 9.0; P = 0.0002). The missense variant I157T was also more frequent in men with prostate cancer (7.8%) than in controls (4.8%), but the relative risk was more modest (OR = 1.7; P = 0.03). I157T was identified in 16% of men with familial prostate cancer (OR = 3.8; P = 0.00002). Loss of the wild-type CHEK2 allele was not observed in any of prostate cancers from five men who carried CHEK2-truncating mutations. Our results provide evidence that the two truncating mutations of CHEK2 confer a moderate risk of prostate cancer in Polish men and that the missense change appears to confer a modest risk.
This article has been cited by other articles:
|
|
 |
|
  C Cybulski, B Gorski, T Huzarski, T Byrski, J Gronwald, T Debniak, D Wokolorczyk, A Jakubowska, P Serrano-Fernandez, T Dork, et al. Effect of CHEK2 missense variant I157T on the risk of breast cancer in carriers of other CHEK2 or BRCA1 mutations J. Med. Genet., February 1, 2009; 46(2): 132 - 135. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. Cybulski, B. Gliniewicz, A. Sikorski, J. Kladny, T. Huzarski, J. Gronwald, T. Byrski, T. Debniak, B. Gorski, A. Jakubowska, et al. Epistatic Relationship between the Cancer Susceptibility Genes CHEK2 and p27 Cancer Epidemiol. Biomarkers Prev., March 1, 2007; 16(3): 572 - 576. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Weischer, S. E. Bojesen, A. Tybjaerg-Hansen, C. K. Axelsson, and B. G. Nordestgaard Increased Risk of Breast Cancer Associated With CHEK2*1100delC J. Clin. Oncol., January 1, 2007; 25(1): 57 - 63. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. Thompson, S. Seal, M. Schutte, L. McGuffog, R. Barfoot, A. Renwick, R. Eeles, N. Sodha, R. Houlston, S. Shanley, et al. A Multicenter Study of Cancer Incidence in CHEK2 1100delC Mutation Carriers Cancer Epidemiol. Biomarkers Prev., December 1, 2006; 15(12): 2542 - 2545. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 X. Wang, F. Wang, K. Taniguchi, R. S. Seelan, L. Wang, K. E. Zarfas, S. K. McDonnell, C. Qian, K. Pan, Y. Lu, et al. Truncating Variants in p53AIP1 Disrupting DNA Damage-Induced Apoptosis Are Associated with Prostate Cancer Risk Cancer Res., November 1, 2006; 66(21): 10302 - 10307. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C Cybulski, D Wokolorczyk, T Huzarski, T Byrski, J Gronwald, B Gorski, T Debniak, B Masojc, A Jakubowska, B Gliniewicz, et al. A large germline deletion in the Chek2 kinase gene is associated with an increased risk of prostate cancer J. Med. Genet., November 1, 2006; 43(11): 863 - 866. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. Cybulski, B. Gorski, T. Huzarski, T. Byrski, J. Gronwald, T. Debniak, D. Wokolorczyk, A. Jakubowska, E. Kowalska, O. Oszurek, et al. CHEK2-Positive Breast Cancers in Young Polish Women. Clin. Cancer Res., August 15, 2006; 12(16): 4832 - 4835. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
O Kilpivaara, P Alhopuro, P Vahteristo, L A Aaltonen, and H Nevanlinna CHEK2 I157T associates with familial and sporadic colorectal cancer. J. Med. Genet., July 1, 2006; 43(7): e34 - e34. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 T. Walsh, S. Casadei, K. H. Coats, E. Swisher, S. M. Stray, J. Higgins, K. C. Roach, J. Mandell, M. K. Lee, S. Ciernikova, et al. Spectrum of Mutations in BRCA1, BRCA2, CHEK2, and TP53 in Families at High Risk of Breast Cancer JAMA, March 22, 2006; 295(12): 1379 - 1388. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
E. L. Kwak, S. Kim, J. Zhang, R. D. Cardiff, E. V. Schmidt, and D. A. Haber Mammary Tumorigenesis following Transgenic Expression of a Dominant Negative CHK2 Mutant Cancer Res., February 15, 2006; 66(4): 1923 - 1928. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C Hughes, A Murphy, C Martin, O Sheils, and J O'Leary Molecular pathology of prostate cancer J. Clin. Pathol., July 1, 2005; 58(7): 673 - 684. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T. Debniak, R. J. Scott, T. Huzarski, T. Byrski, A. Rozmiarek, B. Debniak, E. Zaluga, R. Maleszka, J. Kladny, B. Gorski, et al. CDKN2A Common Variants and Their Association with Melanoma Risk: A Population-Based Study Cancer Res., February 1, 2005; 65(3): 835 - 839. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Kammerer, R. B. Roth, R. Reneland, G. Marnellos, C. R. Hoyal, N. J. Markward, F. Ebner, M. Kiechle, U. Schwarz-Boeger, L. R. Griffiths, et al. Large-Scale Association Study Identifies ICAM Gene Region as Breast and Prostate Cancer Susceptibility Locus Cancer Res., December 15, 2004; 64(24): 8906 - 8910. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Cancer Research | Clinical Cancer Research |
| Cancer Epidemiology Biomarkers & Prevention | Molecular Cancer Therapeutics |
| Molecular Cancer Research | Cancer Prevention Research |
| Cancer Prevention Journals Portal | Cancer Reviews Online |
| Annual Meeting Education Book | Meeting Abstracts Online |
